Oldsmobiles
liked
It’s all red but where is Santa? Where are the gifts? How avout the Christmas rally?
Nothing goes up forever, when it’s time for the fall, it just fall. You can lame it on FED or Powell but this pull back is a healthy one and an opportunity to buy the dip.
Once stable, we will probably see the the stocks trading around the same level until early next year. Hopefully by then the earnings season will provide some fuel for the stocks to move up.
$Eli Lilly and Co (LLY.US)$ $Tesla (TSLA.US)$ $Advanced Micro Devices (AMD.US)$ $Apple (AAPL.US)$ $Novo-Nordisk A/S (NVO.US)$ $Arm Holdings (ARM.US)$
...
Nothing goes up forever, when it’s time for the fall, it just fall. You can lame it on FED or Powell but this pull back is a healthy one and an opportunity to buy the dip.
Once stable, we will probably see the the stocks trading around the same level until early next year. Hopefully by then the earnings season will provide some fuel for the stocks to move up.
$Eli Lilly and Co (LLY.US)$ $Tesla (TSLA.US)$ $Advanced Micro Devices (AMD.US)$ $Apple (AAPL.US)$ $Novo-Nordisk A/S (NVO.US)$ $Arm Holdings (ARM.US)$
...
29
13
Oldsmobiles
liked
$Aptose Biosciences (APTO.US)$ Why is there cooperation with the country but no one is buying?
Bullish news provided by Chat GPT
Aptose Biosciences has recently received multiple bullish news:
1. Nasdaq Listing Qualification Extension: On December 19, 2024, the company announced that the Nasdaq Listing Qualifications Hearings Panel agreed to grant Aptose an extension, requiring the company to meet the minimum Shareholder Equity and minimum Stock Price requirements by March 31, 2025, to continue to maintain its listing qualification. 
2. Preclinical data publication: On December 12, 2024, the company published preclinical data on its main drug Tuspetinib in the journal "Cancer Drug Communication", demonstrating the unique mechanism of action of the drug, as well as its synergistic lethal effect on Acute Myeloid Leukemia (AML) cells when used in combination with Venetoclax.
3. At the ASH annual meeting in December 9, 2024, Aptose Biosciences presented clinical data on the triple combination therapy of Tuspetinib for newly diagnosed AML patients in the USA, emphasizing its broad efficacy and good safety profile in FLT3 wild-type and previously Venetoclax-treated patients.
4. In December 3, 2024, the company signed a cooperation research and development agreement with the National Cancer Institute (NCI) in the USA.
Bullish news provided by Chat GPT
Aptose Biosciences has recently received multiple bullish news:
1. Nasdaq Listing Qualification Extension: On December 19, 2024, the company announced that the Nasdaq Listing Qualifications Hearings Panel agreed to grant Aptose an extension, requiring the company to meet the minimum Shareholder Equity and minimum Stock Price requirements by March 31, 2025, to continue to maintain its listing qualification. 
2. Preclinical data publication: On December 12, 2024, the company published preclinical data on its main drug Tuspetinib in the journal "Cancer Drug Communication", demonstrating the unique mechanism of action of the drug, as well as its synergistic lethal effect on Acute Myeloid Leukemia (AML) cells when used in combination with Venetoclax.
3. At the ASH annual meeting in December 9, 2024, Aptose Biosciences presented clinical data on the triple combination therapy of Tuspetinib for newly diagnosed AML patients in the USA, emphasizing its broad efficacy and good safety profile in FLT3 wild-type and previously Venetoclax-treated patients.
4. In December 3, 2024, the company signed a cooperation research and development agreement with the National Cancer Institute (NCI) in the USA.
Translated
5
1
Oldsmobiles
voted
The Nasdaq 100 is up to its tricks again, transforming itself every December! 🎄 And guess what? Some major players might just join the $26 trillion club! 💰 $Palantir (PLTR.US)$ is leading the pack, with $MicroStrategy (MSTR.US)$ 💻, $Equinix Inc (EQIX.US)$ 🌐, $CME Group (CME.US)$ 📊, $Interactive Brokers (IBKR.US)$ 📈, and $Coinbase (COIN.US)$ hot on its trail. They're all in line to potentially become $NASDAQ 100 Index (.NDX.US)$ members d...
+3
5
2
1
Oldsmobiles
voted
Tesla fans, the magic number has been hit—$400 in overnight trading! 🎉🔥 That's a new milestone, and the internet is buzzing with screenshots and gains.
🌏 Late-Night Wins!
Shoutout to moomoo for the night trading feature! 🙌 I caught this after-hours rally, and wow, it did not disappoint. 🚀 Honestly, being able to trade at night just proved again that moomoo was the right call. No FOMO here! ✨
🤔 What’s Next?
Could we see $Tesla (TSLA.US)$ sprint toward $450+? Or is a pullback ...
🌏 Late-Night Wins!
Shoutout to moomoo for the night trading feature! 🙌 I caught this after-hours rally, and wow, it did not disappoint. 🚀 Honestly, being able to trade at night just proved again that moomoo was the right call. No FOMO here! ✨
🤔 What’s Next?
Could we see $Tesla (TSLA.US)$ sprint toward $450+? Or is a pullback ...
+1
1
2
1
Oldsmobiles
liked
$Super Micro Computer (SMCI.US)$ This was giving me heart attack for a few weeks, but all worked out fine eventually
15
1
Oldsmobiles
liked
$Super Micro Computer (SMCI.US)$
Don't be so fixated on being bearish, isn't it better to be bullish together? 😓
Don't be so fixated on being bearish, isn't it better to be bullish together? 😓
Translated
5
Oldsmobiles
voted
Hey mooers! Max here, wrapping up our exciting journey through the world of stock selection.
Can you believe how far we've come? Let's take a quick trip down memory lane:
1. We started by peeking into the portfolios of big institutions with the Institutional Tracker.
2. Then we hunted for passive income with the High Dividend Yield screener.
3. We got a bird's-eye view of the market with the Heat Map.
4. We explored entire industri...
Can you believe how far we've come? Let's take a quick trip down memory lane:
1. We started by peeking into the portfolios of big institutions with the Institutional Tracker.
2. Then we hunted for passive income with the High Dividend Yield screener.
3. We got a bird's-eye view of the market with the Heat Map.
4. We explored entire industri...
115
38
23